Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Advancing Microbiome Therapeutics R&D through Application of Omics Technologies
Assembly Biosciences, Inc.
Harnessing the Microbiome: A New Continuum for Therapeutics
Janssen Human Microbiome Institute
R&D and Emerging Technologies for Microbiome Drug Development
Altered microbial communities (dysbiosis) has been observed in many inflammatory disorders but it is not clear whether it is a cause or a consequence of the diseases. A healthy gut microbiota exists in an equilibrium with the gut barrier and the immune system. The importance and design of multiple-target drug cocktails comprising commensal bacteria will be discussed. The bacterial library, screening technologies will be presented with particular focus on successful products that treat Irritable Bowel Syndrome and Clostridium difficile infection.
As published in a recent Scientist Report by l'Oreal and Tokyo University, comparative display of skin microbiome during age in women shows a specific dysbiosis.
This dysbiosis characterized by an Increase of diversity during age associated with a decrease of a strain "gatekeeper" of healthy skin in young people associated with an increase of bacteria living usually in the mouth, during age.
Siolta Therapeutics, a San Francisco based biotech company, is designing next generation microbial therapeutics aimed at the prevention and treatment of inflammatory diseases. Our current focus is on the rational design of a mixed-species microbial consortium for the prevention and treatment of allergic asthma. We are concurrently working towards a future in which the microbiome can help drive patient stratification and tailored microbial therapeutics.
* We have combined a human-first strategy with a multi-omics approach in order to develop an efficacious microbial therapeutic for allergic asthma.
Appreciation for the role of microbes in our lives has been growing rapidly, but the measurement science needed to understand and fully exploit microbial systems has developed at a much slower pace than the industries dependent on them demand. In all applications involving complex microbial communities, the research is hampered by the lack of standards, protocols, and technical infrastructure to allow confidence in the data and comparability. At NIST, we are developing methodologies to enable measurement assurance of complex microbial systems for applications in antimicrobial resistance, in vitro diagnostics, and characterization of microbiomes and biofilms.
The Future of Microbiome Therapeutics
Understanding Mechanisms of Action
Translational and Models for Drug Development
The naked mole-rat (NMR) is a subterranean mouse-sized African mammal that is an excellent model to study the biology of healthy aging and longevity. Here we characterize the intestinal microbial ecosystem of the animal in comparison to humans and other mammals. Compositional gut microbiota peculiarities were shared with human gut microbial ecosystems of centenarians and Hadza hunter-gatherers, considered as models of a healthy gut microbiome. We found an enrichment of short-chain fatty acids and carbohydrate degradation products in naked mole-rat compared to human samples.
Inspirational Speaker: The American Gut Project